Last Week in Biomedicine copertina

Last Week in Biomedicine

Last Week in Biomedicine

Di: TrialBreaks
Ascolta gratuitamente

A proposito di questo titolo

 Every Tuesday, we break down 10 of the most significant biopharma stories and buzzworthy clinical trial breakthroughs from the previous week. The podcast highlights major Phase 2 and Phase 3 trial results, breakthrough therapies, biotech innovations, FDA updates, and emerging treatments shaping the future of medicine. From obesity and cancer to autoimmune disease, neurodegeneration, cardiovascular disease, diabetes, and rare genetic disorders, each episode delivers a fast, accessible look at the data, discoveries, and therapies driving the next generation of healthcare.TrialBreaks Disturbo fisico e malattia Igiene e vita sana
Episodi
  • Last Week in Biomedicine | May 11–15 | Part 1

    Last Week in Biomedicine | May 11–15 | Part 1
    May 19 2026

    Top 10 significant clinical trial results from last week

    Part 1:
    1. REGENXBIO ($RGNX) — RGX-202 microdystrophin gene therapy for Duchenne muscular dystrophy (Phase 3)
    2. Alkermes ($ALKS) — LUMRYZ (sodium oxybate once-nightly) for idiopathic hypersomnia (Phase 3)
    3. Viking Therapeutics ($VKTX) — oral VK2735 (GLP-1/GIP dual agonist) for obesity (Phase 2)
    4. Inhibrx Biosciences ($INBX) — INBRX-106 (hexavalent OX40 agonist) plus pembrolizumab for first-line PD-L1+ head and neck squamous cell carcinoma (Phase 2)
    5. United Therapeutics ($UTHR) — Tyvaso (inhaled treprostinil) for idiopathic pulmonary fibrosis (Phase 3)

    Subscribe for weekly clinical trial breakdowns at TrialBreaks.com
    #biotech #clinicaltrials #pharma #genetherapy #Duchenne #DMD #GLP1 #obesity #oncology #immunotherapy #headandneckcancer #pulmonology #IPF #cysticfibrosis#womenshealth #prostatecancer #glioblastoma #ovariancancer #sleepmedicine
    Mostra di più Mostra meno
    13 min
  • Last Week in Biomedicine | May 4-9

    Last Week in Biomedicine | May 4-9
    May 12 2026

    Last week's biggest biotech story: Cytokinetics hit both dual primary endpoints in the ACACIA-HCM pivotal Phase 3 trial of aficamten in non-obstructive hypertrophic cardiomyopathy — the first cardiac myosin inhibitor to win in nHCM and a major franchise expansion. Moderna's mRNA-1010 flu vaccine also landed in NEJM, and DDW 2026 drove a cluster of IBD readouts.


    This week we cover:

    1. Cytokinetics ($CYTK) — aficamten for non-obstructive hypertrophic cardiomyopathy (Phase 3)

    2. Moderna ($MRNA) — mRNA-1010 seasonal influenza vaccine (Phase 3)

    3. Avalo Therapeutics ($AVTX) — abdakibart (AVTX-009) for hidradenitis suppurativa (Phase 2)

    4. Viridian Therapeutics ($VRDN) — elegrobart for chronic thyroid eye disease (Phase 3)

    5. Johnson & Johnson ($JNJ) — JNJ-4804 (guselkumab + golimumab) for refractory ulcerative colitis and Crohn's disease (Phase 2b)

    6. Bayer ($BAYRY) — asundexian for secondary stroke prevention (Phase 3 OCEANIC-STROKE late-breaking)

    7. AbbVie ($ABBV) — risankizumab (Skyrizi) and upadacitinib (Rinvoq) long-term IBD data (Phase 3)

    8. Eli Lilly ($LLY) — mirikizumab (Omvoh) long-term IBD data (Phase 3)

    9. Nuance Pharma (private) — nafithromycin (MIQNAF) for community-acquired bacterial pneumonia (Phase 3)

    10. Bioxodes (private) — BIOX-101 for intracerebral hemorrhage (Phase 2a)


    The Cytokinetics nHCM win opens up a second indication for aficamten and pressures BMS's Camzyos directly, while Moderna's NEJM publication strengthens its bid for FDA approval and a seasonal flu commercial launch. DDW 2026 was a watershed for combination biologic IBD therapy.


    Subscribe for weekly clinical trial breakdowns at TrialBreaks.com


    #biotech #clinicaltrials #pharma #cardiology #HCM #obesity #vaccines #mRNA #immunology #IBD #ulcerativecolitis #Crohns #neurology #stroke #dermatology #hidradenitis #thyroideyedisease #infectiousdisease
    Mostra di più Mostra meno
    30 min
adbl_web_anon_alc_button_suppression_c
Ancora nessuna recensione